• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 2
  3. Authors

Online ISSN: 2515-8260

Volume7, Issue2

Advances in Kinase Inhibitors Anticancers: Highlights and Challenges

    Ali N. Hussein Zahraa Albasry2

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 2, Pages 20-22

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Protein tyrosine kinase (PTK) is considered as one of the main signaling catalysts during
the transduction of cell signal. The role of PTK is to transfer the ATP-γ-phosphate to the
tyrosine moiety in the targeted protein. This, in turn, resulted in many cellular processes,
including; phosphorylation, controlling cell growth, regulation of the cell differentiation,
apoptosis and many other cellular processes. Accordingly, any faulty expression of PTK
however, resulted in faulty cell multiplication. Nowadays, various PTKs are utilized as
targets for the treatment of cancer.
The mechanism by which the tyrosine kinase inhibitors (TKIs) act as antitumor can be
simplified as the TKIs prevent the ATP from reaching its binding site by competitory
mechanism. This in turn will inhibit the phosphorylation of tyrosine kinase leading to
suppress the tumor cell proliferation. TKIs have gained a great attention by researchers
leading to discover many successful therapies, nevertheless, there are always
challenges to be tackled.
In this work, the authors summarize the mechanism of TKIs, highlighted the successes
and drawbacks of TKIs for anticancer therapies.
Keywords:
    Antitumor Tyrosine kinase inhibitors Protein tyrosine kinase
  • PDF (314 K)
  • XML
(2020). Advances in Kinase Inhibitors Anticancers: Highlights and Challenges. European Journal of Molecular & Clinical Medicine, 7(2), 20-22.
Ali N. Hussein; Zahraa Albasry2. "Advances in Kinase Inhibitors Anticancers: Highlights and Challenges". European Journal of Molecular & Clinical Medicine, 7, 2, 2020, 20-22.
(2020). 'Advances in Kinase Inhibitors Anticancers: Highlights and Challenges', European Journal of Molecular & Clinical Medicine, 7(2), pp. 20-22.
Advances in Kinase Inhibitors Anticancers: Highlights and Challenges. European Journal of Molecular & Clinical Medicine, 2020; 7(2): 20-22.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 232
  • PDF Download: 314
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus